VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) and Sutro Biopharma (NASDAQ:STRO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.
Volatility & Risk
VistaGen Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
Institutional and Insider Ownership
78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
| Sutro Biopharma | 1 | 0 | 10 | 2 | 3.00 |
VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 306.68%. Sutro Biopharma has a consensus price target of $47.30, indicating a potential upside of 205.56%. Given VistaGen Therapeutics’ higher probable upside, research analysts clearly believe VistaGen Therapeutics is more favorable than Sutro Biopharma.
Profitability
This table compares VistaGen Therapeutics and Sutro Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
| Sutro Biopharma | -395.25% | N/A | -88.12% |
Earnings and Valuation
This table compares VistaGen Therapeutics and Sutro Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VistaGen Therapeutics | $1.27 million | 8.16 | -$69.68 million | ($1.66) | -0.14 |
| Sutro Biopharma | $102.48 million | 2.50 | -$191.09 million | ($11.97) | -1.29 |
VistaGen Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Sutro Biopharma beats VistaGen Therapeutics on 9 of the 15 factors compared between the two stocks.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
